Skip to main content
medRxiv
  • Home
  • About
  • Submit
  • ALERTS / RSS
Advanced Search

Systematic benefit-risk assessment for the use of chloroquine or hydroxychloroquine as a treatment for COVID-19: Establishing a framework for rapid decision-making

View ORCID ProfileVicki Osborne, Miranda Davies, Sandeep Dhanda, Debabrata Roy, Samantha Lane, Alison Evans, Saad Shakir
doi: https://doi.org/10.1101/2020.05.07.20093989
Vicki Osborne
1Drug Safety Research Unit’ Southampton’ UK
2School of Pharmacy and Biomedical Sciences’ University of Portsmouth’ Portsmouth’ UK
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • ORCID record for Vicki Osborne
  • For correspondence: vicki.osborne@dsru.org
Miranda Davies
1Drug Safety Research Unit’ Southampton’ UK
2School of Pharmacy and Biomedical Sciences’ University of Portsmouth’ Portsmouth’ UK
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Sandeep Dhanda
1Drug Safety Research Unit’ Southampton’ UK
2School of Pharmacy and Biomedical Sciences’ University of Portsmouth’ Portsmouth’ UK
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Debabrata Roy
1Drug Safety Research Unit’ Southampton’ UK
2School of Pharmacy and Biomedical Sciences’ University of Portsmouth’ Portsmouth’ UK
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Samantha Lane
1Drug Safety Research Unit’ Southampton’ UK
2School of Pharmacy and Biomedical Sciences’ University of Portsmouth’ Portsmouth’ UK
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Alison Evans
1Drug Safety Research Unit’ Southampton’ UK
2School of Pharmacy and Biomedical Sciences’ University of Portsmouth’ Portsmouth’ UK
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Saad Shakir
1Drug Safety Research Unit’ Southampton’ UK
2School of Pharmacy and Biomedical Sciences’ University of Portsmouth’ Portsmouth’ UK
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • Abstract
  • Full Text
  • Info/History
  • Metrics
  • Data/Code
  • Preview PDF
Loading

Abstract

Objectives Given the current pandemic, there is an urgent need to identify effective, safe treatments for COVID-19 (coronavirus disease). A systematic benefit-risk assessment was designed and conducted to strengthen the ongoing monitoring of the benefit-risk balance for chloroquine and hydroxychloroquine in COVID-19 treatment.

Methods The overall benefit-risk of the use of chloroquine or hydroxychloroquine as a treatment for COVID-19 compared to standard of care, placebo or other treatments was assessed using the Benefit-Risk Action Team (BRAT) framework. We searched PubMed and Google Scholar to identify literature reporting clinical outcomes in patients taking chloroquine or hydroxychloroquine for COVID-19. A value tree was constructed and key benefits and risks were ranked by two clinicians in order of considered importance.

Results Several potential key benefits and risks were identified for use of hydroxychloroquine or chloroquine in COVID-19 treatment. For the benefit of virological clearance, three studies were identified. A significant risk difference (RD) between hydroxychloroquine and the comparator group (standard of care) was found for only one study (RD=0.58, 95% CI: 0.17, 0.98). The risk difference was not significant for the other two studies (RD=-0.07, 95% CI:- 0.75, 0.61 and RD=0.08, 95% CI:-0.74, 0.91). In addition, no significant risk difference between hydroxychloroquine and the comparator group (standard of care) was identified for the risk of abnormal liver function tests (LFTs) (RD=0.07, 95% CI: -0.28, 0.41).

Conclusions Overall, no conclusion can be made on the benefit-risk profile of hydroxychloroquine or chloroquine in the treatment of COVID-19 compared to standard of care, placebo or other treatments at this time. Whilst the availability of comparative data are limited, the current framework summarises the key anticipated benefits and risks. As further data from clinical trials and real world use on these benefits and risks becomes available, this can be incorporated into the framework for an ongoing benefit-risk assessment.

Competing Interest Statement

The authors have declared no competing interest.

Funding Statement

The Drug Safety Research Unit (DSRU) is an independent academic institution which works in association with the University of Portsmouth. This research received no specific grant from any funding agency in the public, commercial or not-for-profit sectors

Author Declarations

All relevant ethical guidelines have been followed; any necessary IRB and/or ethics committee approvals have been obtained and details of the IRB/oversight body are included in the manuscript.

Yes

All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.

Yes

I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).

Yes

I have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.

Yes

Data Availability

Data used in this analysis are available from the references supplied.

Copyright 
The copyright holder for this preprint is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. It is made available under a CC-BY-ND 4.0 International license.
Back to top
PreviousNext
Posted May 12, 2020.
Download PDF
Data/Code
Email

Thank you for your interest in spreading the word about medRxiv.

NOTE: Your email address is requested solely to identify you as the sender of this article.

Enter multiple addresses on separate lines or separate them with commas.
Systematic benefit-risk assessment for the use of chloroquine or hydroxychloroquine as a treatment for COVID-19: Establishing a framework for rapid decision-making
(Your Name) has forwarded a page to you from medRxiv
(Your Name) thought you would like to see this page from the medRxiv website.
CAPTCHA
This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.
Share
Systematic benefit-risk assessment for the use of chloroquine or hydroxychloroquine as a treatment for COVID-19: Establishing a framework for rapid decision-making
Vicki Osborne, Miranda Davies, Sandeep Dhanda, Debabrata Roy, Samantha Lane, Alison Evans, Saad Shakir
medRxiv 2020.05.07.20093989; doi: https://doi.org/10.1101/2020.05.07.20093989
Digg logo Reddit logo Twitter logo Facebook logo Google logo LinkedIn logo Mendeley logo
Citation Tools
Systematic benefit-risk assessment for the use of chloroquine or hydroxychloroquine as a treatment for COVID-19: Establishing a framework for rapid decision-making
Vicki Osborne, Miranda Davies, Sandeep Dhanda, Debabrata Roy, Samantha Lane, Alison Evans, Saad Shakir
medRxiv 2020.05.07.20093989; doi: https://doi.org/10.1101/2020.05.07.20093989

Citation Manager Formats

  • BibTeX
  • Bookends
  • EasyBib
  • EndNote (tagged)
  • EndNote 8 (xml)
  • Medlars
  • Mendeley
  • Papers
  • RefWorks Tagged
  • Ref Manager
  • RIS
  • Zotero
  • Tweet Widget
  • Facebook Like
  • Google Plus One

Subject Area

  • Public and Global Health
Subject Areas
All Articles
  • Addiction Medicine (174)
  • Allergy and Immunology (420)
  • Anesthesia (97)
  • Cardiovascular Medicine (896)
  • Dentistry and Oral Medicine (169)
  • Dermatology (102)
  • Emergency Medicine (257)
  • Endocrinology (including Diabetes Mellitus and Metabolic Disease) (405)
  • Epidemiology (8764)
  • Forensic Medicine (4)
  • Gastroenterology (404)
  • Genetic and Genomic Medicine (1857)
  • Geriatric Medicine (177)
  • Health Economics (387)
  • Health Informatics (1286)
  • Health Policy (642)
  • Health Systems and Quality Improvement (490)
  • Hematology (206)
  • HIV/AIDS (392)
  • Infectious Diseases (except HIV/AIDS) (10543)
  • Intensive Care and Critical Care Medicine (564)
  • Medical Education (193)
  • Medical Ethics (52)
  • Nephrology (218)
  • Neurology (1748)
  • Nursing (102)
  • Nutrition (265)
  • Obstetrics and Gynecology (342)
  • Occupational and Environmental Health (460)
  • Oncology (962)
  • Ophthalmology (281)
  • Orthopedics (107)
  • Otolaryngology (176)
  • Pain Medicine (117)
  • Palliative Medicine (41)
  • Pathology (263)
  • Pediatrics (556)
  • Pharmacology and Therapeutics (264)
  • Primary Care Research (218)
  • Psychiatry and Clinical Psychology (1841)
  • Public and Global Health (3975)
  • Radiology and Imaging (650)
  • Rehabilitation Medicine and Physical Therapy (341)
  • Respiratory Medicine (534)
  • Rheumatology (215)
  • Sexual and Reproductive Health (178)
  • Sports Medicine (166)
  • Surgery (196)
  • Toxicology (37)
  • Transplantation (106)
  • Urology (79)